Apotex submits supplemental application for Pomalidomide (ANDA 210164)
Apotex has submitted a supplemental application for Pomalidomide under ANDA 210164.
Published: July 31, 2026
Updated: July 31, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Small Molecule
Asset: Apotex
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Apotex
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The submission of a supplemental application for Pomalidomide by Apotex signals an intent to enhance their oncology portfolio, which could disrupt existing market dynamics. Pharma strategy teams should closely monitor the FDA's review process and potential impacts on pricing and competition.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approval announcements for this application.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.